Inhibition of the expression of p42MAPK in HeLa cell line by RNA interference

Chinese Journal of Pathology

Volumn 35, Issue 5, 2006, Pages 292-295

  Huang, Chen ^a   Liu, Li Ying ^c   Song, Tu Sheng ^c   Ni, Lei ^c   Song, Li Ping ^c   Hu, Jing Song ^c   Zhao, Xiao Ge ^c   Si, Lü Sheng ^b  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c NONE

Author keywords

HeLa cell; Neoplasms, experimental; p42 MAP kinase

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; SMALL INTERFERING RNA;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RNA INTERFERENCE; WESTERN BLOTTING; BIOSYNTHESIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; GENETICS;

CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; FLOW CYTOMETRY; HELA CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 33745789192     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat, 2003, 21:271-276.
2. Opalka B, Dickopp A, Kirch HC. Apoptotic genes in cancer therapy. Cells Tissues Organs, 2002, 172:126-132.
3. Jiang GL, Huang S. Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers. Cancer Res, 2001, 61:1796-1798.
4. Wacheck V, Selzer E, Gunsberg P, et al. Bcl-x (L) antisense oligonucleotides radiosensitise colon cancer cells. Br J Cancer, 2003, 89:1352-1357.
5. Seo YR, Kelley MR, Smith ML. Selenomethionine regulation of p53 by a ref1 -dependent redox mechanism. Proc Natl Acad Sci U S A, 2002, 99:14548-14553.
6. Bos JL. All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral. EMBO J, 1998, 17:6776-6782.
7. Gao J, Niwa K, Takemura M, et al. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Int J Oncol, 2005, 26:737-744.
8. Hellstrom I, Goodman G, Pullman J, et al. Hellstrom KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Res, 2001, 61:2420-2423.
9. Branca M, Ciotti M, Santini D, et al. Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol, 2004, 122:902-911.
10. Tamemoto H, Kadowaki T, Tobes K, et al. Biphasic activation of two mitogen-activated protein kinases during the cell cycle in mammalian cells. J Biol Chem, 1992, 267:20293-20297.
11. McManus MT, Sharp PA. Gene silencing in mammalians by small interferencing RNAs. Nat Rev Genet, 2002, 3:737-747.
12. Aza-Blanc P, Cooper CL, Wagner K, et al. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell, 2003, 12:627-637.
13. Reynolds A, Leake D, Boese Q, et al. Rational siRNA design for RNA interference. Nat Biotechnol, 2004, 22:326-330.
14. Chalk AM, Wahlestedt C, Sonnhammer ELL. Improved and automated prediction of effective siRNA. Biochem Biophys Res Commun, 2004, 319:264-274.